Hepion Pharmaceuticals
Edison
About Hepion Pharmaceuticals
Hepion Pharmaceuticals provides the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The company is a biopharmaceutical business that specializes in the creation of medication therapies for the management of chronic liver illnesses. Hepion Pharmaceuticals was established in 2013.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $143.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: nasdaq:CTRV
- Website: hepionpharma.com
- Phone: +1 732 902-4000
Industries & Categories
Biotechnology, Life Science, Medical, Pharmaceutical, Service Industry
Social Profiles
Canonical: https://fsome.com/organization/hepion-pharmaceuticals-122975 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.